References
- Pai M, Behr MA, Dowdy D, et al. Tuberculosis. Nat Rev Dis Primers. 2016;2:16076.
- Glynn JR. Resurgence of tuberculosis and the impact of HIV infection. Br Med Bull. 1998;54(3):579–593.
- Bell LCK, Noursadeghi M. Pathogenesis of HIV-1 and Mycobacterium tuberculosis co-infection. Nat Rev Microbiol. 2018; 16(2):80–90.
- Mlcochova P, Sutherland KA, Watters SA, et al. A G1-like state allows HIV-1 to bypass SAMHD1 restriction in macrophages. Embo J. 2017;36(5):604–616. 1
- Global tuberculosis report 2022. Geneva: World Health organization; 2022. [Internet]. [Cited 2023 Oct 15]. Available from: https://www.who.int/teams/global-tuberculosis-programme/tb-reports.
- Badri M, Wilson D, Wood R. Effect of highly active antiretroviral therapy on incidence of tuberculosis in South Africa: a cohort study. Lancet. 2002;359(9323):2059–2064.
- Lawn SD, Badri M, Wood R. Tuberculosis among HIV-infected patients receiving HAART: long term incidence and risk factors in a South African cohort. AIDS. 2005;19(18):2109–2116.
- Kabali C, Mtei L, Brooks DR, et al. Increased mortality associated with treated active tuberculosis in HIV-infected adults in Tanzania. Tuberculosis (Edinb). 2013;93(4):461–466.
- Gatechompol S, Sophonphan J, Ubolyam S, et al. Incidence and factors associated with active tuberculosis among people living with HIV after long-term antiretroviral therapy in Thailand: a competing risk model. BMC Infect Dis. 2022;22(1):346.
- Suwanpimolkul G, Gatechompol S, Kawkitinarong K, et al. Incidence of active tuberculosis among people living with HIV receiving long-term antiretroviral therapy in high TB/HIV burden settings in Thailand: implication for tuberculosis preventive therapy. J Int AIDS Soc. 2022;25(4):e25900.
- Dravid A, Natarajan K, Medisetty M, et al. Incidence of tuberculosis among HIV infected individuals on long term antiretroviral therapy in private healthcare sector in pune, Western India. BMC Infect Dis. 2019;19(1):714.
- Girardi E, Sabin CA, d‘Arminio Monforte A, et al. Antiretroviral therapy cohort collaboration. Incidence of tuberculosis among HIV-infected patients receiving highly active antiretroviral therapy in Europe and North America. Clin Infect Dis. 2005;41(12):1772–1782.
- Liu E, Makubi A, Drain P, et al. Tuberculosis incidence rate and risk factors among HIV-infected adults with access to antiretroviral therapy. AIDS. 2015;29(11):1391–1399.
- Gupta RK, Lucas SB, Fielding KL, et al. Prevalence of tuberculosis in post-mortem studies of HIV-infected adults and children in resource-limited settings: a systematic review and meta-analysis. AIDS. 2015;29(15):1987–2002.
- Principi N, Autore G, Ramundo G, et al. Epidemiology of respiratory infections during the COVID-19 pandemic. Viruses. 2023;15(5):1160.
- Chow EJ, Uyeki TM, Chu HY. The effects of the COVID-19 pandemic on community respiratory virus activity. Nat Rev Microbiol. 2023;21(3):195–210.
- Emery JC, Richards AS, Dale KD, et al. Self-clearance of Mycobacterium tuberculosis infection: implications for lifetime risk and population at-risk of tuberculosis disease. Proc Biol Sci. 2021;288(1943):20201635.
- แนวทางการตรวจรักษาและป้องกันการติดเชื้อเอชไอวี ประเทศไทย ปี 2564/2565. (Thailand National Guidelines on HIV/AIDS Treatment and Prevention 2021/2022) [Internet]. [Cited 2023 October 20]. Available from: https://www.thaiaidssociety.org/thailand-hiv-aids-guideline/.
- Humphry RW, Cameron A, Gunn GJ. A practical approach to calculate sample size for herd prevalence surveys. Prev Vet Med. 2004;65(3-4):173–188.
- Sample size to estimate a true prevalence with an imperfect test. [Internet]. [Cited 2023 October 1]. Available from: https://epitools.ausvet.com.au/prevalencess
- Saeed M, Hussain S, Riaz S, et al. GeneXpert technology for the diagnosis of HIV-associated tuberculosis: is scale-up worth it? Open Life Sci. 2020;15(1):458–465.
- Hermans SM, Kiragga AN, Schaefer P, et al. Incident tuberculosis during antiretroviral therapy contributes to suboptimal immune reconstitution in a large urban HIV clinic in Sub-Saharan Africa. PLoS One. 2010;5(5):e10527.
- Haddow LJ, Moosa MY, Mosam A, et al. Incidence, clinical spectrum, risk factors and impact of HIV-associated immune reconstitution inflammatory syndrome in South Africa. PLoS One. 2012;7(11):e40623.
- Danel C, Moh R, Gabillard D, et al. A trial of early antiretrovirals and isoniazid preventive therapy in Africa. N Engl J Med. 2015;373(9):808–822.
- Consolidated guidelines on HIV prevention, testing. treatment, service delivery and monitoring: recommendations for a public health approach. Geneva: World Health Organization; 2021 [Internet]. [Cited 2023 October 15]. Available from: https://www.who.int/publications/i/item/9789240031593.
- Clinical Practice Guideline Tuberculosis Preventive Treatment. 2023Internet]. [Cited 2023 October 15]. Available from: http://www.tbthailand.org/download/Manual/แนวทางเวชปฏิบัติ%20วัณโรคระยะแฝง%. 202566%20CPG-TPT%202023.pdf.
- Nyangu S, Kagujje M, Mwaba I, et al. Breakthrough TB among people living with HIV on TB preventive therapy. Public Health Action. 2022;12(4):153–158.
- Dhana A, Hamada Y, Kengne AP, et al. Tuberculosis screening among ambulatory people living with HIV: a systematic review and individual participant data meta-analysis. Lancet Infect Dis. 2022;22(4):507–518.
- Chitpim N, Jittikoon J, Udomsinprasert W, et al. Cost-Utility analysis of molecular testing for tuberculosis diagnosis in suspected pulmonary tuberculosis in Thailand. Clinicoecon Outcomes Res. 2022;14:61–73.
- National Tuberculosis Control Programme Guideline of Thailand. 2021 [Internet]. [Cited 2023 October 15]. Available from: https://ddc.moph.go.th/uploads/publish/1253220220330064337.pdf.
- Bhatia V, Srivastava R, Reddy KS, et al. Ending TB in Southeast Asia: current resources are not enough. BMJ Glob Health. 2020;5(3):e002073.